Cancer Consumer Groups Oppose Oncologic Surrogates Citing WHI Experience
Executive Summary
The Women's Health Initiative experience suggests that surrogate endpoints should not be used in oncology, several cancer and consumer advocacy organizations state in a letter to FDA Commissioner McClellan
You may also be interested in...
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
FDA is changing its accelerated approval guidelines to allow for approval of several different oncologic agents for the same indication under Subpart H procedures, Commissioner McClellan said during the American Society of Clinical Oncology annual meeting in Chicago May 31
NIH Has Room For Improvement In Releasing Study Data – WHI Director
The National Institutes of Health can improve its methods for releasing study data, Women's Health Initiative Director Barbara Alving, MD, said
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention